KOL R&D Day - Cognitive Impairment Associated with Schizophrenia (CIAS)

An atai Life Sciences event featuring a presentation by Key Opinion Leader (KOL) Richard S.E. Keefe, PhD, of Duke University.

Dr. Keefe discussed the current treatment landscape and unmet medical need in treating patients with Cognitive Impairment Associated with Schizophrenia (CIAS), followed by Matthew Pando, PhD, CEO and Co-Founder of Recognify Life Sciences, who discussed the design of the completed Phase 2a trial for RL-007 and the preliminary topline data.

The event took place on January 18, 2022, at 12 PM ET. For those who were unable to listen at the time, a replay of the call is available here.